Consequently, the higher carnitine levels observed in the CSF of the GBM patients evaluated here may be facilitated by upregulation of OCTN2, which in turn could potentially be a response to greater demand for carnitine by enhanced fatty acid oxidation in GBM. Here, SLC22A5 is linked to glioblastoma.